Review



randomisation list  (Minitab Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Minitab Inc randomisation list
    Randomisation List, supplied by Minitab Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/computer+generated+list+randomization/pmc13055410-68-35-38
    Average 86 stars, based on 1 article reviews
    randomisation list - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: Engineering mechanical gradients in next generation biomaterials - Lessons learned from medical textile design.
    Article Snippet: Compression sleeve sections and swatch alignments were tested as a randomised trial and were analysed initially using a general linear model in Minitab (Minitab Inc., State College, PA).

    Article Title: Novel sources of resistance to Striga hermonthica in Tripsacum dactyloides, a wild relative of maize.
    Article Snippet: Statistical analyses The influence of S. hermonthica on the biomass of its host, parasite biomass supported by each host and the development of the parasite were analysed using analysis of variance procedures for a randomised design (Minitab statistical package, version 10.2, Minitab Inc., Pensylvania, USA).

    Article Title: Growth performance and blood indices of growing turkeys fed diets containing shrimp waste meal
    Article Snippet: Data obtained were fitted into one‐way Analysis of Variance (ANOVA) in a Completely Randomised Design using the general linear model procedure of the Minitab version 17.

    Article Title: Effect of Different Packaging Atmosphere on Microbiological Shelf Life, Physicochemical Attributes, and Sensory Characteristics of Chilled Poultry Fillets
    Article Snippet: The data were analysed under a complete randomised design through two-way ANOVA by Minitab (Minitab 17.3.1).

    Generated:

    Article Title: Model establishment based on clinical data from patient monitors: Optimising night-time alarms in intensive care units.
    Article Snippet: Objectives: The purpose of this study is to establish a model correlating the number of alarms and effective alarms on a monitor, and to use this model to optimise night-time alarm issues in intensive care units in order to reduce alarm fatigue among night shift nurses.. Methods: A retrospective study method was used to track 1,843 samples.. Based on partial experimental design analysis, a model for ‘alarm frequency’ and ‘effective alarms’ was established for the monitor, which was then optimised using the composite centre factorial (CCF) method.

    Software:

    Article Title: Lead (Pb2+) adsorption by means of pristine and prewashed residual Moringa oleifera Lam. seed husk biomass for water treatment applications
    Article Snippet: Moringa oleifera Lam. (MO) seed husk waste was used to remove Pb during batch and filtration processes, from lead-containing water.. MO husk biomass was used in its pristine (i.e. unwashed) and prewashed forms.. Adsorption was described by the Dubinin-Radushkevich model (qm 3.719 [mg Pb/g MO husk], K = 1.116×10 [mol/J]).

    Blocking Assay:

    Article Title: Orthodontic treatment for prominent upper front teeth (Class II malocclusion) in children and adolescents
    Article Snippet: .. Al Baath University, Syria Recruitment period: registered patients in pending records Funding source: not specified Trial design: parallel group RCT Participants Inclusion criteria: skeletal Class II division 1 malocclusion resulting from the retrusion of the mandible (SNB angle < 78°); convex facial profile; ANB angle > 4°; good mouth health; no previous orthodontic treatments; pubertal growth spurt peak at the beginning of the treatment, which was assessed using hand-wrist radiographs according to the Fishman method Exclusion criteria: none specified Age at baseline: Bite Jumping Appliance group 11.5 years (SD 1.0), Twin Block 11.8 years (SD 0.9) Number randomised: 44 (22 in each group) Number evaluated: 40 Interventions Gp A (n = 20): Bite jumping appliance - removable functional appliance Gp B (n = 20): Twin Block appliance - removable functional appliance Outcomes Using cephalometric radiograms, the dentoalveolar and skeletal effects resulting from both appliances were detected Notes Duration of active treatment - 12 months + recruited period (not reported) Sample size: to determine the appropriate sample size, the Minitab software was used with two-sample t-tests, a selected study power of 80%, a significance level of 0.05, and a detected difference of 1°. ..

    Functional Assay:

    Article Title: Orthodontic treatment for prominent upper front teeth (Class II malocclusion) in children and adolescents
    Article Snippet: .. Al Baath University, Syria Recruitment period: registered patients in pending records Funding source: not specified Trial design: parallel group RCT Participants Inclusion criteria: skeletal Class II division 1 malocclusion resulting from the retrusion of the mandible (SNB angle < 78°); convex facial profile; ANB angle > 4°; good mouth health; no previous orthodontic treatments; pubertal growth spurt peak at the beginning of the treatment, which was assessed using hand-wrist radiographs according to the Fishman method Exclusion criteria: none specified Age at baseline: Bite Jumping Appliance group 11.5 years (SD 1.0), Twin Block 11.8 years (SD 0.9) Number randomised: 44 (22 in each group) Number evaluated: 40 Interventions Gp A (n = 20): Bite jumping appliance - removable functional appliance Gp B (n = 20): Twin Block appliance - removable functional appliance Outcomes Using cephalometric radiograms, the dentoalveolar and skeletal effects resulting from both appliances were detected Notes Duration of active treatment - 12 months + recruited period (not reported) Sample size: to determine the appropriate sample size, the Minitab software was used with two-sample t-tests, a selected study power of 80%, a significance level of 0.05, and a detected difference of 1°. ..



    Similar Products

    � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc  (Thermo Fisher)
    99
    Thermo Fisher � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc
    � Fsc Corrected Fsc Unmasked Fsc Masked Fsc Phase Randomised 0 75xk10 Peg Pbs B Dc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/PHOSPHATE+BUFFERED+SALINE+PBS/pm33724780__nn0c10137_si_001-14-69-109
    Average 99 stars, based on 1 article reviews
    � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation list  (Minitab Inc)
    86
    Minitab Inc randomisation list
    Randomisation List, supplied by Minitab Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/computer+generated+list+randomization/pmc13055410-68-35-38
    Average 86 stars, based on 1 article reviews
    randomisation list - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    gcp compliant randomisation system  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals gcp compliant randomisation system
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Gcp Compliant Randomisation System, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/compliant+gcp+randomisation+system/pmc12969703-132-9-12
    Average 86 stars, based on 1 article reviews
    gcp compliant randomisation system - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    randomisation  (STATA Corporation)
    99
    STATA Corporation randomisation
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/STATA+12%2E0/pmc12960068-56-0-4
    Average 99 stars, based on 1 article reviews
    randomisation - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation sequence  (STATA Corporation)
    99
    STATA Corporation randomisation sequence
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation Sequence, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/STATA+15%2E0/pm41549406-39-1-6
    Average 99 stars, based on 1 article reviews
    randomisation sequence - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    pre randomisation tumour specimen  (Foundation Medicine Inc)
    99
    Foundation Medicine Inc pre randomisation tumour specimen
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Pre Randomisation Tumour Specimen, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/FoundationOne+CDx/pm41422862-70-13-20
    Average 99 stars, based on 1 article reviews
    pre randomisation tumour specimen - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation list  (Novartis)
    86
    Novartis randomisation list
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation List, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/list+randomisation/10__1002_slash_14651858__cd009885__pub4-5010-38-10
    Average 86 stars, based on 1 article reviews
    randomisation list - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    tayside randomisation system trust  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals tayside randomisation system trust
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Tayside Randomisation System Trust, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/compliant+gcp+randomisation+system/10__1183_slash_23120541__00719___2025-296-236-236
    Average 86 stars, based on 1 article reviews
    tayside randomisation system trust - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    randomisation system  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals randomisation system
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation System, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomised/compliant+gcp+randomisation+system/10__1183_slash_23120541__00719___2025-209-12-14
    Average 86 stars, based on 1 article reviews
    randomisation system - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for randomisation when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.

    Journal: ERJ Open Research

    Article Title: Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network

    doi: 10.1183/23120541.00719-2025

    Figure Lengend Snippet: AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for randomisation when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.

    Article Snippet: Randomisation will be done via the centrally controlled, web-based, GCP-compliant randomisation system, Tayside Randomisation System (TRuST), run by the Health Informatics Centre (University of Dundee), with allocation provided via email.

    Techniques: Control, Activity Assay, Comparison